Get the Stockscreener App
1.14
0.88%
0.01
After Hours:
1.18
0.04
+3.51%
Context Therapeutics Inc stock is traded at $1.14, with a volume of 236.89K.
It is up +0.88% in the last 24 hours and up +38.79% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.13
Open:
$1.17
24h Volume:
236.89K
Relative Volume:
1.19
Market Cap:
$102.26M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-1.2527
EPS:
-0.91
Net Cash Flow:
$-31.63M
1W Performance:
+17.54%
1M Performance:
+38.79%
6M Performance:
+70.40%
1Y Performance:
-38.71%
1-Day Range:
$1.14
$1.22
1-Week Range:
$0.9767
$1.29
52-Week Range:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.14 | 101.37M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Consensus PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Hire - MSN
Will Context Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
Context Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual Meeting - Quiver Quantitative
Context Therapeutics Announces Poster Presentations at the - GlobeNewswire
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of ... - Caledonian Record
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Context Therapeutics Inc. stock momentum explainedWeekly Stock Analysis & Fast Momentum Stock Entry Tips - newser.com
Is it too late to sell Context Therapeutics Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Context Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - MarketScreener
Developing predictive dashboards with Context Therapeutics Inc. dataJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recoveryEarnings Growth Report & Verified Technical Signals - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics announces inducement grant under Nasdaq listing rule - MarketScreener
GlobeNewswire by Notified - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
30,000-Share Option: Context Therapeutics Grants New Hire Award at $0.97 Exercise Price, 10-year Term - Stock Titan
Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st
Is Context Therapeutics Inc. stock in correction or buying zoneWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Is Context Therapeutics Inc. showing signs of accumulation2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Cantor Fitzgerald Initiates Coverage of Context Therapeutics (CNTX) with Overweight Recommendation - Nasdaq
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
How Context Therapeutics Inc. stock trades before earningsRate Cut & Reliable Breakout Forecasts - newser.com
What analysts say about Context Therapeutics Inc stockPortfolio Diversification Tips & Tap Into the Fastest-Growing Companies - earlytimes.in
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Context Therapeutics Inc Stock (CNTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):